Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Xbrane Biopharma AB (7XB0) AI Stock Analysis

6 Followers
DE:7XB0

Xbrane Biopharma AB

(Frankfurt:7XB0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong TTM Revenue GrowthRevenue growth of 53.6% indicates meaningful commercial expansion in the latest trailing period. If sustained, increased scale can broaden the company’s biosimilar market presence, support operating leverage, and improve the foundation for future profitability.
Negative Factors
Persistent Net LossesThe company remains materially unprofitable despite strong TTM revenue growth. Continued net losses and negative operating margins weaken internal funding capacity, make earnings less predictable, and show that commercial expansion has not yet translated into sustainable operating economics.

Xbrane Biopharma AB (7XB0) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%DE:7XB0+20.38%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 21.71M
Dividend Yield
―
Average Volume (3M)
491
Price to Earnings (P/E)
-6.3
Beta (1Y)
1.14
Revenue Growth
-37.13%
EPS Growth
-119.85%
Country
Germany
Employees
28
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xbrane Biopharma AB Business Overview & Revenue Model

Company Description

Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibi...

Xbrane Biopharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7XB0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA61NeutralSEK 395.00M2.0463.09%―――
SE:HNSASE:HNSA53NeutralSEK 4.71B-5.93――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ELICSE:ELIC47NeutralSEK 173.51M-7.31-56.09%――14.10%
SE:BINVSE:BINV43NeutralSEK 192.15M-0.39-128.54%―-83.67%-50.29%
SE:ATORXSE:ATORX39UnderperformSEK 32.47M-0.01-439.98%―-99.33%64.90%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:7XB0SE:HNSASE:ATORXSE:BINVSE:ELICSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7XB0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7XB0Xbrane Biopharma AB1.010.1719.67%
SE:HNSAHansa Biopharma46.8420.6078.51%
SE:ATORXAlligator Bioscience AB0.01-0.19-95.05%
SE:BINVBioInvent International AB2.92-26.98-90.25%
SE:ELICElicera Therapeutics AB2.58-2.68-50.86%
SE:CANTACantargia AB1.39-2.06-59.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.